124 related articles for article (PubMed ID: 22766431)
1. Skin lesions and treatment with tumor necrosis factor alpha antagonists.
Hernández MV; Meineri M; Sanmartí R
Reumatol Clin; 2013; 9(1):53-61. PubMed ID: 22766431
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous lupus erythematosus induced by the treatment with tumor necrosis factor antagonists.
Sifuentes Giraldo WA; Ahijón Lana M; Vázquez Díaz M
Reumatol Clin; 2013; 9(4):255-6. PubMed ID: 23608052
[No Abstract] [Full Text] [Related]
3. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
[TBL] [Abstract][Full Text] [Related]
4. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
[TBL] [Abstract][Full Text] [Related]
5. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
6. Granuloma annulare induced by anti-tumour necrosis factor therapy.
Voulgari PV; Markatseli TE; Exarchou SA; Zioga A; Drosos AA
Ann Rheum Dis; 2008 Apr; 67(4):567-70. PubMed ID: 17728330
[TBL] [Abstract][Full Text] [Related]
7. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis infections and tumor necrosis factor alpha antagonists.
Gan J; Manadan AM; Sequiera W; Block JA
Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
[TBL] [Abstract][Full Text] [Related]
9. [TNF-alpha inhibitors and demyelinating disease].
Böttiger Y
Lakartidningen; 2007 Nov 7-13; 104(45):3384. PubMed ID: 18062640
[No Abstract] [Full Text] [Related]
10. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
[No Abstract] [Full Text] [Related]
11. Thromboembolic events and anti-tumor necrosis factor therapies.
Masson PL
Int Immunopharmacol; 2012 Dec; 14(4):444-5. PubMed ID: 22954485
[TBL] [Abstract][Full Text] [Related]
12. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
[No Abstract] [Full Text] [Related]
13. Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.
Rongioletti F; Burlando M; Parodi A
G Ital Dermatol Venereol; 2014 Jun; 149(3):311-6. PubMed ID: 24819758
[TBL] [Abstract][Full Text] [Related]
14. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
Dinarello CA
J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
[TBL] [Abstract][Full Text] [Related]
15. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
Richette P; Viguier M; Bachelez H; Bardin T
J Rheumatol; 2007 Feb; 34(2):438-9. PubMed ID: 17304662
[No Abstract] [Full Text] [Related]
16. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
17. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.
Ubriani R; Van Voorhees AS
Arch Dermatol; 2007 Feb; 143(2):270-2. PubMed ID: 17310016
[No Abstract] [Full Text] [Related]
18. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept.
Hu S; Cohen D; Murphy G; Mody E; Qureshi AA
Cutis; 2008 Apr; 81(4):336-8. PubMed ID: 18491481
[TBL] [Abstract][Full Text] [Related]
19. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
[TBL] [Abstract][Full Text] [Related]
20. Problems encountered during anti-tumour necrosis factor therapy.
Desai SB; Furst DE
Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
